Skip to content
DataLookout
Menu

NCT07447817

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 2 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Start date: May 4, 2026 to Oct 23, 2026
    • Eligibility criteria expanded, about 40 words
    • Secondary endpoints: details revised at 6 of 10 entries
    • Site details revised at 3 of 3 sites
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in spleen volume
Timeframe: Baseline and 24 weeks

Secondary (10)

Spleen response rate
Change in the Myelofibrosis-Symptom Assessment Form Total Symptom Score (MF-SAF TSS)
Change in Patient Global Impression of Change (PGIC)
Anemia response
Change in hemoglobin level
Show 5 moreShow less
Change in platelet count
Progression-free survival
Overall survival
Number of participants achieving RBC transfusion independence)
Number of participants achieving platelet transfusion independence

Arms and interventions

Pacritinib/SelinexorExperimental

Study participants will receive pacritinib monotherapy (200mg BID orally) for the first cycle (28 days). If they qualify to add on selinexor at any point from Cycle 2 Day 1 to Cycle 4 Day 1, participants will have selinexor (60mg QW orally) added onto their pacritinib regimen.

Drugs: Pacritinib, Selinexor

Sites

3 sites in 1 country